PDB Short entry for 2RL5 HEADER TRANSFERASE 18-OCT-07 2RL5 TITLE CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A 2,3- TITLE 2 DIHYDRO-1,4-BENZOXAZINE INHIBITOR COMPND MOL_ID: 1; COMPND 2 MOLECULE: VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: PROTEIN KINASE DOMAIN, RESIDUES 940-989 DELETED; COMPND 5 SYNONYM: VEGFR-2, KINASE INSERT DOMAIN RECEPTOR, PROTEIN-TYROSINE COMPND 6 KINASE RECEPTOR FLK-1, CD309 ANTIGEN; COMPND 7 EC: 2.7.10.1; COMPND 8 ENGINEERED: YES; COMPND 9 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: KDR, FLK1; SOURCE 6 EXPRESSION_SYSTEM: TRICHOPLUSIA NI; SOURCE 7 EXPRESSION_SYSTEM_COMMON: CABBAGE LOOPER; SOURCE 8 EXPRESSION_SYSTEM_TAXID: 7111; SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: BACULOVIRUS KEYWDS RECEPTOR TYROSINE KINASE, ANGIOGENESIS, ATP-BINDING, DEVELOPMENTAL KEYWDS 2 PROTEIN, DIFFERENTIATION, GLYCOPROTEIN, HOST-VIRUS INTERACTION, KEYWDS 3 IMMUNOGLOBULIN DOMAIN, MEMBRANE, NUCLEOTIDE-BINDING, KEYWDS 4 PHOSPHORYLATION, POLYMORPHISM, TRANSFERASE, TRANSMEMBRANE, TYROSINE- KEYWDS 5 PROTEIN KINASE EXPDTA X-RAY DIFFRACTION AUTHOR D.A.WHITTINGTON,A.M.LONG,P.ROSE,H.ZHAO REVDAT 6 21-FEB-24 2RL5 1 REMARK REVDAT 5 20-OCT-21 2RL5 1 REMARK SEQADV REVDAT 4 13-NOV-19 2RL5 1 KEYWDS REVDAT 3 26-JUL-17 2RL5 1 SOURCE REVDAT 2 24-FEB-09 2RL5 1 VERSN REVDAT 1 08-APR-08 2RL5 0 JRNL AUTH D.S.LA,J.BELZILE,J.V.BREADY,A.COXON,T.DEMELFI,N.DOERR, JRNL AUTH 2 J.ESTRADA,J.C.FLYNN,S.R.FLYNN,R.F.GRACEFFA,S.P.HARRIMAN, JRNL AUTH 3 J.F.LARROW,A.M.LONG,M.W.MARTIN,M.J.MORRISON,V.F.PATEL, JRNL AUTH 4 P.M.ROVETO,L.WANG,M.M.WEISS,D.A.WHITTINGTON,Y.TEFFERA, JRNL AUTH 5 Z.ZHAO,A.J.POLVERINO,J.C.HARMANGE JRNL TITL NOVEL 2,3-DIHYDRO-1,4-BENZOXAZINES AS POTENT AND ORALLY JRNL TITL 2 BIOAVAILABLE INHIBITORS OF TUMOR-DRIVEN ANGIOGENESIS. JRNL REF J.MED.CHEM. V. 51 1695 2008 JRNL REFN ISSN 0022-2623 JRNL PMID 18311900 JRNL DOI 10.1021/JM701129J REMARK 2 REMARK 2 RESOLUTION. 2.65 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : ENGH & HUBER REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.65 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 30.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 10000.000 REMARK 3 DATA CUTOFF LOW (ABS(F)) : 0.0000 REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 99.9 REMARK 3 NUMBER OF REFLECTIONS : 16246 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.199 REMARK 3 FREE R VALUE : 0.233 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 7.800 REMARK 3 FREE R VALUE TEST SET COUNT : 1268 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : NULL REMARK 3 BIN RESOLUTION RANGE HIGH (A) : NULL REMARK 3 BIN RESOLUTION RANGE LOW (A) : NULL REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 REFLECTIONS IN BIN (WORKING SET) : NULL REMARK 3 BIN R VALUE (WORKING SET) : NULL REMARK 3 BIN FREE R VALUE : NULL REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 BIN FREE R VALUE TEST SET COUNT : NULL REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2370 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 35 REMARK 3 SOLVENT ATOMS : 139 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 32.60 REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 1.20100 REMARK 3 B22 (A**2) : -4.03100 REMARK 3 B33 (A**2) : 2.83000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.30 REMARK 3 ESD FROM SIGMAA (A) : 0.29 REMARK 3 LOW RESOLUTION CUTOFF (A) : 5.00 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.36 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.31 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.006 REMARK 3 BOND ANGLES (DEGREES) : 1.200 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 21.10 REMARK 3 IMPROPER ANGLES (DEGREES) : 0.770 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : NULL REMARK 3 KSOL : NULL REMARK 3 BSOL : NULL REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : NULL REMARK 3 TOPOLOGY FILE 1 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 2RL5 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 01-NOV-07. REMARK 100 THE DEPOSITION ID IS D_1000044992. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 11-JAN-05 REMARK 200 TEMPERATURE (KELVIN) : 97 REMARK 200 PH : 8.2 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ALS REMARK 200 BEAMLINE : 5.0.2 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : NULL REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC QUANTUM 315 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 16281 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.650 REMARK 200 RESOLUTION RANGE LOW (A) : 30.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : -3.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.9 REMARK 200 DATA REDUNDANCY : 4.800 REMARK 200 R MERGE (I) : 0.11500 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 13.7000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.65 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.74 REMARK 200 COMPLETENESS FOR SHELL (%) : 99.6 REMARK 200 DATA REDUNDANCY IN SHELL : 4.60 REMARK 200 R MERGE FOR SHELL (I) : 0.43700 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : 3.400 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: FOURIER SYNTHESIS REMARK 200 SOFTWARE USED: CNS REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 66.90 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 3.72 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: PEG 4000, LITHIUM SULFATE, TRIS, PH REMARK 280 8.2, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 277K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 2 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,-Y,Z REMARK 290 3555 -X+1/2,Y+1/2,-Z REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 33.38000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 69.88700 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 33.38000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 69.88700 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 843 REMARK 465 ALA A 844 REMARK 465 PHE A 845 REMARK 465 ALA A 1050 REMARK 465 ARG A 1051 REMARK 465 ASP A 1052 REMARK 465 ILE A 1053 REMARK 465 PTR A 1054 REMARK 465 LYS A 1055 REMARK 465 ASP A 1056 REMARK 465 PRO A 1057 REMARK 465 ASP A 1058 REMARK 465 PTR A 1059 REMARK 465 VAL A 1060 REMARK 465 ARG A 1061 REMARK 465 LYS A 1062 REMARK 465 GLY A 1063 REMARK 465 HIS A 1176 REMARK 465 HIS A 1177 REMARK 465 HIS A 1178 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 LYS A 858 43.21 -92.75 REMARK 500 ALA A 860 137.02 176.88 REMARK 500 LYS A 871 -178.07 -67.32 REMARK 500 VAL A 899 120.26 -35.94 REMARK 500 ARG A1027 -16.94 80.71 REMARK 500 ASP A1028 53.43 -147.00 REMARK 500 ASP A1112 -163.48 -112.84 REMARK 500 REMARK 500 REMARK: NULL REMARK 600 REMARK 600 HETEROGEN REMARK 600 REMARK 600 TYR1054 AND TYR1059 WERE PHOSPHORYLATED BY AN AUTOPHOSPHORYLATION REMARK 600 REACTION RUN ON THE PROTEIN PRIOR TO CRYSTALLIZATION. THE REMARK 600 PHOSPHORYLATED TYR IS REPRESENTED BY PTR, PHOSPHONOTYROSINE, REMARK 600 PTR1054 AND PTR1059. THESE RESIDUES ARE PART OF THE KINASE REMARK 600 ACTIVATION LOOP AND THEY ARE DISORDERED IN THE STRUCTURE AND REMARK 600 CONSEQUENTLY NOT SEEN IN THE ELECTRON DENSITY. REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 2RL A 501 DBREF 2RL5 A 815 939 UNP P35968 VGFR2_HUMAN 815 939 DBREF 2RL5 A 990 1171 UNP P35968 VGFR2_HUMAN 990 1171 SEQADV 2RL5 ALA A 817 UNP P35968 CYS 817 ENGINEERED MUTATION SEQADV 2RL5 THR A 916 UNP P35968 VAL 916 ENGINEERED MUTATION SEQADV 2RL5 VAL A 990 UNP P35968 GLU 990 ENGINEERED MUTATION SEQRES 1 A 314 GLU HIS ALA GLU ARG LEU PRO TYR ASP ALA SER LYS TRP SEQRES 2 A 314 GLU PHE PRO ARG ASP ARG LEU LYS LEU GLY LYS PRO LEU SEQRES 3 A 314 GLY ARG GLY ALA PHE GLY GLN VAL ILE GLU ALA ASP ALA SEQRES 4 A 314 PHE GLY ILE ASP LYS THR ALA THR CYS ARG THR VAL ALA SEQRES 5 A 314 VAL LYS MET LEU LYS GLU GLY ALA THR HIS SER GLU HIS SEQRES 6 A 314 ARG ALA LEU MET SER GLU LEU LYS ILE LEU ILE HIS ILE SEQRES 7 A 314 GLY HIS HIS LEU ASN VAL VAL ASN LEU LEU GLY ALA CYS SEQRES 8 A 314 THR LYS PRO GLY GLY PRO LEU MET VAL ILE THR GLU PHE SEQRES 9 A 314 CYS LYS PHE GLY ASN LEU SER THR TYR LEU ARG SER LYS SEQRES 10 A 314 ARG ASN GLU PHE VAL PRO TYR LYS VAL ALA PRO GLU ASP SEQRES 11 A 314 LEU TYR LYS ASP PHE LEU THR LEU GLU HIS LEU ILE CYS SEQRES 12 A 314 TYR SER PHE GLN VAL ALA LYS GLY MET GLU PHE LEU ALA SEQRES 13 A 314 SER ARG LYS CYS ILE HIS ARG ASP LEU ALA ALA ARG ASN SEQRES 14 A 314 ILE LEU LEU SER GLU LYS ASN VAL VAL LYS ILE CYS ASP SEQRES 15 A 314 PHE GLY LEU ALA ARG ASP ILE PTR LYS ASP PRO ASP PTR SEQRES 16 A 314 VAL ARG LYS GLY ASP ALA ARG LEU PRO LEU LYS TRP MET SEQRES 17 A 314 ALA PRO GLU THR ILE PHE ASP ARG VAL TYR THR ILE GLN SEQRES 18 A 314 SER ASP VAL TRP SER PHE GLY VAL LEU LEU TRP GLU ILE SEQRES 19 A 314 PHE SER LEU GLY ALA SER PRO TYR PRO GLY VAL LYS ILE SEQRES 20 A 314 ASP GLU GLU PHE CYS ARG ARG LEU LYS GLU GLY THR ARG SEQRES 21 A 314 MET ARG ALA PRO ASP TYR THR THR PRO GLU MET TYR GLN SEQRES 22 A 314 THR MET LEU ASP CYS TRP HIS GLY GLU PRO SER GLN ARG SEQRES 23 A 314 PRO THR PHE SER GLU LEU VAL GLU HIS LEU GLY ASN LEU SEQRES 24 A 314 LEU GLN ALA ASN ALA GLN GLN ASP ARG HIS HIS HIS HIS SEQRES 25 A 314 HIS HIS HET 2RL A 501 35 HETNAM 2RL N-(4-CHLOROPHENYL)-7-[(6,7-DIMETHOXYQUINOLIN-4-YL)OXY]- HETNAM 2 2RL 2,3-DIHYDRO-1,4-BENZOXAZINE-4-CARBOXAMIDE FORMUL 2 2RL C26 H22 CL N3 O5 FORMUL 3 HOH *139(H2 O) HELIX 1 1 HIS A 816 LEU A 820 5 5 HELIX 2 2 ASP A 823 GLU A 828 1 6 HELIX 3 3 PRO A 830 ASP A 832 5 3 HELIX 4 4 THR A 875 GLY A 893 1 19 HELIX 5 5 ASN A 923 SER A 930 1 8 HELIX 6 6 PRO A 992 LYS A 997 5 6 HELIX 7 7 THR A 1001 ARG A 1022 1 22 HELIX 8 8 ALA A 1030 ARG A 1032 5 3 HELIX 9 9 LEU A 1067 MET A 1072 5 6 HELIX 10 10 ALA A 1073 ARG A 1080 1 8 HELIX 11 11 THR A 1083 PHE A 1099 1 17 HELIX 12 12 ASP A 1112 GLU A 1121 1 10 HELIX 13 13 THR A 1132 TRP A 1143 1 12 HELIX 14 14 GLU A 1146 ARG A 1150 5 5 HELIX 15 15 THR A 1152 GLN A 1169 1 18 SHEET 1 A 5 LEU A 834 GLY A 841 0 SHEET 2 A 5 GLN A 847 ASP A 857 -1 O GLU A 850 N GLY A 837 SHEET 3 A 5 ALA A 860 MET A 869 -1 O THR A 861 N GLY A 855 SHEET 4 A 5 MET A 913 GLU A 917 -1 O VAL A 914 N LYS A 868 SHEET 5 A 5 LEU A 901 CYS A 905 -1 N LEU A 902 O ILE A 915 SHEET 1 B 2 ILE A1034 LEU A1036 0 SHEET 2 B 2 VAL A1042 ILE A1044 -1 O LYS A1043 N LEU A1035 CISPEP 1 ALA A 991 PRO A 992 0 -0.08 SITE 1 AC1 13 LEU A 840 ALA A 866 GLU A 885 LEU A 889 SITE 2 AC1 13 THR A 916 GLU A 917 PHE A 918 CYS A 919 SITE 3 AC1 13 LEU A1019 LEU A1035 CYS A1045 ASP A1046 SITE 4 AC1 13 PHE A1047 CRYST1 66.760 139.774 57.550 90.00 90.00 90.00 P 21 21 2 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.014979 0.000000 0.000000 0.00000 SCALE2 0.000000 0.007154 0.000000 0.00000 SCALE3 0.000000 0.000000 0.017376 0.00000